Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial) von Meunier, Matthias E., Neuzillet, Yann, Raynaud, Jean‐Pierre, Radulescu, Camelia, Ghoneim, Tarek, Fiet, Jean, Giton, Franck, Rouanne, Mathieu, Dreyfus, Jean‐François, Lebret, Thierry, Botto, Henry

Volltext

Sexual steroids in serum and prostatic tissue of human non‐cancerous prostate (STERPROSER trial) von Neuzillet, Yann, Raynaud, Jean‐Pierre, Radulescu, Camélia, Fiet, Jean, Giton, Franck, Dreyfus, Jean‐François, Ghoneim, Tarek P., Lebret, Thierry, Botto, Henry

Volltext

PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study von Meunier, Matthias E., Neuzillet, Yann, Dreyfus, Jean-François, Schneider, Marc, Rouprêt, Morgan, Cathelineau, Xavier, Raynaud, Jean-Pierre, Lebret, Thierry, Botto, Henry

Volltext

Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy von Neuzillet, Yann, Dreyfus, Jean-François, Raynaud, Jean-Pierre, Rouanne, Mathieu, Schneider, Marc, Roupret, Morgan, Drouin, Sarah, Galiano, Marc, Cathelineau, Xavier, Lebret, Thierry, Botto, Henry

Volltext

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy von Neuzillet, Yann, Rouanne, Mathieu, Dreyfus, Jean-François, Raynaud, Jean-Pierre, Schneider, Marc, Roupret, Morgan, Drouin, Sarah, Galiano, Marc, Cathelinau, Xavier, Lebret, Thierry, Botto, Henry

Volltext

Prostate‐specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment von Raynaud, Jean‐Pierre, Gardette, Jean, Rollet, Jacques, Legros, Jean‐Jacques

Volltext

Prostate cancer risk in testosterone-treated men von Raynaud, Jean-Pierre

Volltext

Testosterone deficiency syndrome: Treatment and cancer risk von Raynaud, Jean-Pierre

Volltext

Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients—PERMAL Study Subset Analysis von Debruyne, Frans, Boyle, Peter, Calais Da Silva, Fernando, Gillenwater, Jay G, Hamdy, Freddie C, Perrin, Paul, Teillac, Pierre, Vela-Navarrete, Remigio, Raynaud, Jean-Pierre, Schulman, Claude C

Volltext

Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients von Carraro, Jean-Christophe, Raynaud, Jean-Pierre, Koch, Gary, Chisholm, Geoffrey D., Di Silverio, Franco, Teillac, Pierre, Da Silva, Fernando Calais, Cauquil, Joris, Chopin, Dominique K., Hamdy, Freddie C., Hanus, Miroslav, Hauri, Dieter, Kalinteris, Athanasios, Marencak, Josef, Perier, Antoine, Perrin, Paul

Volltext

Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results von Neuzillet, Yann, Raynaud, Jean-Pierre, Dreyfus, Jean-François, Radulescu, Camélia, Rouanne, Mathieu, Schneider, Marc, Krish, Sylvie, Rouprêt, Morgan, Drouin, Sarah J., Comperat, Eva, Galiano, Marc, Cathelineau, Xavier, Validire, Pierre, Molinié, Vincent, Fiet, Jean, Giton, Franck, Lebret, Thierry, Botto, Henry

Volltext

Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride von Van Coppenolle, Fabien, Le Bourhis, Xuefen, Carpentier, Françoise, Delaby, Geoffrey, Cousse, Henri, Raynaud, Jean-Pierre, Dupouy, Jean-Paul, Prevarskaya, Natalia

Volltext

Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia von Vacherot, Francis, Azzouz, Mohamed, Gil-Diez-de-Medina, Sixtina, Colombel, Marc, De La Taille, Alexandre, Lefrère Belda, Marie-Aude, Abbou, Claude C., Raynaud, Jean-Pierre, Chopin, Dominique K.

Volltext

Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditions von Raynaud, Jean-Pierre, Augès, Marie, Liorzou, Laurent, Turlier, Virginie, Lauze, Christophe

Volltext

Comparison of a Phytotherapeutic Agent (Permixon) with an α-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study von Debruyne, Frans, Koch, Gary, Boyle, Peter, Da Silva, Fernando Calais, Gillenwater, Jay G., Hamdy, Freddie C., Perrin, Paul, Teillac, Pierre, Vela-Navarrete, Remigio, Raynaud, Jean-Pierre

Volltext

Serum Bioavailable Testosterone: Assayed or Calculated? von Giton, Frank, Fiet, Jean, Guechot, Jerome, Ibrahim, Fidaa, Bronsard, Francoise, Chopin, Dominique, Raynaud, Jean-Pierre

Volltext

Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon von Raynaud, Jean-Pierre, Cousse, Henri, Martin, Pierre-Marie

Volltext

Hormones in normal and pathological prostate von Saad, Farid, Raynaud, Jean-Pierre

Volltext

Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men von Raynaud, Jean-Pierre, Legros, Jean-Jacques, Rollet, Jacques, Augès, Marie, Bunouf, Pierre, Sournac, Michel, Fiet, Jean

Volltext

Estrone sulfate (E 1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa) von Giton, Frank, de la Taille, Alexandre, Allory, Yves, Galons, Hervé, Vacherot, Francis, Soyeux, Pascale, Abbou, Claude Clément, Loric, Sylvain, Cussenot, Olivier, Raynaud, Jean-Pierre, Fiet, Jean

Volltext